Re‐exploring immune‐related side effects of docetaxel in an observational study: Blood hypereosinophilia
Abstract Docetaxel is a major anticancer drug that can induce hypersensitivity reactions leading to deleterious treatment interruptions. Blood hypereosinophilia could be a biological sign, potentially lethal, of delayed visceral hypersensitivity reactions. We hypothesized this biological event is pr...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-05-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2062 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846166583053910016 |
|---|---|
| author | Diaddin Hamdan Christophe Leboeuf Christine Le Foll Guilhem Bousquet Anne Janin |
| author_facet | Diaddin Hamdan Christophe Leboeuf Christine Le Foll Guilhem Bousquet Anne Janin |
| author_sort | Diaddin Hamdan |
| collection | DOAJ |
| description | Abstract Docetaxel is a major anticancer drug that can induce hypersensitivity reactions leading to deleterious treatment interruptions. Blood hypereosinophilia could be a biological sign, potentially lethal, of delayed visceral hypersensitivity reactions. We hypothesized this biological event is probably underreported. In this prospective observational study, we followed up 149 patients treated with docetaxel monotherapy for breast or lung cancer. For each patient, blood eosinophil counts were recorded during docetaxel treatment and up to 3 months after the end of docetaxel treatment. For all patients, blood eosinophil counts significantly increased under docetaxel chemotherapy (P < 0.01). Seven percent had persistent eosinophilia after the end of treatment. Four patients had blood eosinophil counts over 1000/mm3 with severe cardiac, cutaneous and digestive toxicities, and docetaxel imputability was confirmed using drug‐imputability scales. For two of these four patients, tissue biopsies were performed during the time of hypereosinophilia and of severe toxicities. Specific immunostainings and electron microscopy found numerous degranulating mast cells and eosinophils. Our study demonstrated that eosinophilia is frequent under docetaxel and could lead to severe complications, implicating eosinophils and mast cells, and possibly IgE. One way of treating hypersensitivity reactions could be by targeting IgEs with omalizumab, an anti‐IgE monoclonal antibody approved for the treatment of severe allergic asthma, and successfully used in food and poison‐induced anaphylactic reactions. |
| format | Article |
| id | doaj-art-0b4bf24119304104a4e7f093494e0c0f |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2019-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-0b4bf24119304104a4e7f093494e0c0f2024-11-15T13:01:04ZengWileyCancer Medicine2045-76342019-05-01852005201210.1002/cam4.2062Re‐exploring immune‐related side effects of docetaxel in an observational study: Blood hypereosinophiliaDiaddin Hamdan0Christophe Leboeuf1Christine Le Foll2Guilhem Bousquet3Anne Janin4Medical Oncology Department Grand Hospital of East Francilien‐Marne‐la‐Vallée Jossigny FranceUMR_S1165, Inserm University of Paris‐Diderot Paris FranceMedical Oncology Department Grand Hospital of East Francilien‐Marne‐la‐Vallée Jossigny FranceUMR_S1165, Inserm University of Paris‐Diderot Paris FranceUMR_S1165, Inserm University of Paris‐Diderot Paris FranceAbstract Docetaxel is a major anticancer drug that can induce hypersensitivity reactions leading to deleterious treatment interruptions. Blood hypereosinophilia could be a biological sign, potentially lethal, of delayed visceral hypersensitivity reactions. We hypothesized this biological event is probably underreported. In this prospective observational study, we followed up 149 patients treated with docetaxel monotherapy for breast or lung cancer. For each patient, blood eosinophil counts were recorded during docetaxel treatment and up to 3 months after the end of docetaxel treatment. For all patients, blood eosinophil counts significantly increased under docetaxel chemotherapy (P < 0.01). Seven percent had persistent eosinophilia after the end of treatment. Four patients had blood eosinophil counts over 1000/mm3 with severe cardiac, cutaneous and digestive toxicities, and docetaxel imputability was confirmed using drug‐imputability scales. For two of these four patients, tissue biopsies were performed during the time of hypereosinophilia and of severe toxicities. Specific immunostainings and electron microscopy found numerous degranulating mast cells and eosinophils. Our study demonstrated that eosinophilia is frequent under docetaxel and could lead to severe complications, implicating eosinophils and mast cells, and possibly IgE. One way of treating hypersensitivity reactions could be by targeting IgEs with omalizumab, an anti‐IgE monoclonal antibody approved for the treatment of severe allergic asthma, and successfully used in food and poison‐induced anaphylactic reactions.https://doi.org/10.1002/cam4.2062allergic reactionanticancer treatmentdocetaxeleosinophiliahypersensitivity |
| spellingShingle | Diaddin Hamdan Christophe Leboeuf Christine Le Foll Guilhem Bousquet Anne Janin Re‐exploring immune‐related side effects of docetaxel in an observational study: Blood hypereosinophilia Cancer Medicine allergic reaction anticancer treatment docetaxel eosinophilia hypersensitivity |
| title | Re‐exploring immune‐related side effects of docetaxel in an observational study: Blood hypereosinophilia |
| title_full | Re‐exploring immune‐related side effects of docetaxel in an observational study: Blood hypereosinophilia |
| title_fullStr | Re‐exploring immune‐related side effects of docetaxel in an observational study: Blood hypereosinophilia |
| title_full_unstemmed | Re‐exploring immune‐related side effects of docetaxel in an observational study: Blood hypereosinophilia |
| title_short | Re‐exploring immune‐related side effects of docetaxel in an observational study: Blood hypereosinophilia |
| title_sort | re exploring immune related side effects of docetaxel in an observational study blood hypereosinophilia |
| topic | allergic reaction anticancer treatment docetaxel eosinophilia hypersensitivity |
| url | https://doi.org/10.1002/cam4.2062 |
| work_keys_str_mv | AT diaddinhamdan reexploringimmunerelatedsideeffectsofdocetaxelinanobservationalstudybloodhypereosinophilia AT christopheleboeuf reexploringimmunerelatedsideeffectsofdocetaxelinanobservationalstudybloodhypereosinophilia AT christinelefoll reexploringimmunerelatedsideeffectsofdocetaxelinanobservationalstudybloodhypereosinophilia AT guilhembousquet reexploringimmunerelatedsideeffectsofdocetaxelinanobservationalstudybloodhypereosinophilia AT annejanin reexploringimmunerelatedsideeffectsofdocetaxelinanobservationalstudybloodhypereosinophilia |